Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03458130 · ClinicalTrials.gov registry record · Phase 2
Study of AG10 in Amyloid Cardiomyopathy
A Phase 2 study of Familial ATTR-CM (ATTRm-CM, or FAC) and Wild-type ATTR-CM (ATTRwt-CM), sponsored by Eidos Therapeutics, a BridgeBio company.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
- 13
- Study locations
NCT03458130: Completed Phase 2 study of Familial ATTR-CM (ATTRm-CM, or FAC) and Wild-type ATTR-CM (ATTRwt-CM), sponsored by Eidos Therapeutics, a BridgeBio company.
NCT03458130 is a Phase 2 study of Familial ATTR-CM (ATTRm-CM, or FAC) and Wild-type ATTR-CM (ATTRwt-CM) that has completed, run by Eidos Therapeutics, a BridgeBio company. The registered enrollment target is 49 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (63% lower). The trial reports 13 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03458130, a Phase 2 study of Familial ATTR-CM (ATTRm-CM, or FAC) and Wild-type ATTR-CM (ATTRwt-CM), has completed, sponsored by Eidos Therapeutics, a BridgeBio company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
- 13
- Study locations
Study Summary
This prospective, randomized, multicenter, double-blind, parallel group, placebo-controlled, dose-ranging study will evaluate the safety, tolerability, PK (Pharmacokinetic) and PD (Pharmacodynamic) of AG10 compared to placebo administered on a background of stable heart failure therapy. Screening and randomization will be followed by a 28-day blinded, placebo-controlled treatment period.
Primary Outcome
Change in Diastolic Blood Pressure from Baseline to Day 28 (Postdose)
Conditions Studied
Interventions
- DRUG Placebo Oral Tablet
- DRUG AG10
Study Locations (13)
California
- Cedars-Sinai Medical Center - Beverly Hills
- Stanford University - Palo Alto
- University of California San Francisco - San Francisco
Massachusetts
- Brigham and Women's Hospital - Boston
- Boston University - Boston
Connecticut
- Yale University - New Haven
Illinois
- Northwestern University - Chicago
Minnesota
- Mayo Clinic - Rochester
New York
- Columbia University - New York
Ohio
- Cleveland Clinic - Cleveland
Oregon
- Oregon Health & Science University - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2018-04-27 |
| Est. Completion | 2018-10-05 |
| Phase | Phase 2 |
What the finished NCT03458130 record still lists
NCT03458130 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (63% lower).
The record links to 2 conditions, with Familial ATTR-CM (ATTRm-CM, or FAC) appearing as the primary indexed condition, and to 2 interventions - of which Placebo Oral Tablet is the first listed.
NCT03458130 lists 13 locations in 10 states (California, Massachusetts, Connecticut).
Frequently Asked Questions
What is clinical trial NCT03458130 about?
NCT03458130 is a clinical study titled "Study of AG10 in Amyloid Cardiomyopathy". This prospective, randomized, multicenter, double-blind, parallel group, placebo-controlled, dose-ranging study will evaluate the safety, tolerability, PK (Pharmacokinetic) and PD (Pharmacodynamic) of AG10 compared to placebo administered on a background of stable heart failure therapy. Screening an...
What is the current status of trial NCT03458130?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2018-04-27. Estimated completion is 2018-10-05.
What conditions does trial NCT03458130 study?
This clinical trial studies the following conditions: Familial ATTR-CM (ATTRm-CM, or FAC), Wild-type ATTR-CM (ATTRwt-CM).
What interventions are being tested in trial NCT03458130?
The interventions under investigation include: Placebo Oral Tablet (DRUG), AG10 (DRUG).
Who is sponsoring clinical trial NCT03458130?
This trial is sponsored by Eidos Therapeutics, a BridgeBio company, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03458130 being conducted?
This trial has 13 study locations across California, Connecticut, Illinois, Massachusetts, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03458130's enrollment target sits among peer trials
49 1261st of 2000 higher than 736 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI